Tagrisso approved in Japan for early lung cancer
25 August 2022 07:05 BST Tagrisso approved in Japan for the adjuvant treatment ofpatients with early-stage EGFR-mutated lung cancer Tagrisso is the only EGFR-targeted medicine approved in Japan for thetreatment of early-stage lung cancer after surgery Approval based on results from the ADAURA Phase III trial AstraZeneca's Tagrisso (osimertinib) has been approved in Japan for the adjuvant treatment of patients with epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after surgery. This approval by the Japanese Ministry of Health, Labour and